CISG [FANHUA] 6-K: (Original Filing)

[Fanhua Reports Second Quarter and First Half 2018 Unaudited Financial Results And Declares Quarterly Dividend of US$0.25 Per ADS — Full Year Operating Income Guidance Revised Upwards to 50% Growth YoY — Quarterly Diluted Net Income Per ADS US$0.40, Up 20.0% YoY 1 GUANGZHOU, China, August 20, 2018 (G]

By | 2018-08-21T12:00:32+00:00 August 21st, 2018|Categories: Chinese Stocks, CISG, SEC Original|Tags: , , , , , |0 Comments

CISG [FANHUA] 6-K: Fanhua Reports Second Quarter and First Half 2018

[Fanhua Reports Second Quarter and First Half 2018 Unaudited Financial Results And Declares Quarterly Dividend of US$0.25 Per ADS — Full Year Operating Income Guidance Revised Upwards to 50% Growth YoY — Quarterly Diluted Net Income Per ADS US$0.40, Up 20.0% YoY 1 GUANGZHOU, China, August 20, 2018 (G]

By | 2018-08-21T12:00:36+00:00 August 21st, 2018|Categories: Chinese Stocks, CISG, Webplus ver|Tags: , , , , , |0 Comments

CHA [CHINA TELECOM] 6-K: Number Page 1.1 Announcement in relation to proposed

[Number Page 1.1 Announcement in relation to proposed appointment of supervisor, dated August 20, 2018 A-1 1.2 Announcement in relation to renewal of continuing connected transactions, dated August 20, 2018 B-1 6-K •]

By | 2018-08-21T12:00:58+00:00 August 21st, 2018|Categories: CHA, Chinese Stocks, Webplus ver|Tags: , , , , , |0 Comments

NQ [Link Motion] 6-K: (Original Filing)

[Link Motion Joins Travel Service Platform Fliggy BEIJING - August 21, 2018 -- Link Motion will serve as a service provider for travelers visiting certain “smart scenic spots” in Hangzhou, which are popular tourist attractions supported by Fliggy’s technology to provide visitors with a smart tour exp]

By | 2018-08-21T12:01:07+00:00 August 21st, 2018|Categories: Chinese Stocks, NQ, SEC Original|Tags: , , , , , |0 Comments

NQ [Link Motion] 6-K: Link Motion Joins Travel Service Platform Fliggy BEIJING

[Link Motion Joins Travel Service Platform Fliggy BEIJING - August 21, 2018 -- Link Motion will serve as a service provider for travelers visiting certain “smart scenic spots” in Hangzhou, which are popular tourist attractions supported by Fliggy’s technology to provide visitors with a smart tour exp]

By | 2018-08-21T12:01:13+00:00 August 21st, 2018|Categories: Chinese Stocks, NQ, Webplus ver|Tags: , , , , , |0 Comments

TEDU [Tarena International] 6-K: (Original Filing)

[Tarena International, Inc. Announces Second Quarter 2018 Results Second Quarter Net Revenues up by 13.6% Year-Over-Year Second Quarter Student Enrollment in adult up by 21.6% Year-Over-Year Second Quarter Student Enrollment in kid education programs up by 512.8 Year-Over-Year BEIJING, August 20, 201]

By | 2018-08-21T12:01:27+00:00 August 21st, 2018|Categories: Chinese Stocks, SEC Original, TEDU|Tags: , , , , , |0 Comments

TEDU [Tarena International] 6-K: Tarena International, Inc. Announces Second Quarter 2018 Results

[Tarena International, Inc. Announces Second Quarter 2018 Results Second Quarter Net Revenues up by 13.6% Year-Over-Year Second Quarter Student Enrollment in adult up by 21.6% Year-Over-Year Second Quarter Student Enrollment in kid education programs up by 512.8 Year-Over-Year BEIJING, August 20, 201]

By | 2018-08-21T12:01:32+00:00 August 21st, 2018|Categories: Chinese Stocks, TEDU, Webplus ver|Tags: , , , , , |0 Comments

CBPO [China Biologic Products] 6-K: (Original Filing)

[FOR RELEASE August 21, 2018 China Biologic Announces Receipt of Competing Non-Binding Acquisition Proposal BEIJING, China — August 21, 2018 — About China Biologic Products Holdings, Inc. China Biologic Products Holdings, Inc. (NASDAQ: CBPO) is a leading fully integrated plasma-based biopharmaceutica]

CBPO [China Biologic Products] 6-K: FOR RELEASE August 21, 2018 China Biologic Announces

[FOR RELEASE August 21, 2018 China Biologic Announces Receipt of Competing Non-Binding Acquisition Proposal BEIJING, China — August 21, 2018 — About China Biologic Products Holdings, Inc. China Biologic Products Holdings, Inc. (NASDAQ: CBPO) is a leading fully integrated plasma-based biopharmaceutica]

Skip to toolbar